Jane Healy

2.4k total citations · 1 hit paper
27 papers, 772 citations indexed

About

Jane Healy is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jane Healy has authored 27 papers receiving a total of 772 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jane Healy's work include Cancer Immunotherapy and Biomarkers (13 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Jane Healy is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Jane Healy collaborates with scholars based in United States, South Korea and Israel. Jane Healy's co-authors include Vann Bennett, Sandeep S. Davé, Talia Golan, Kathryn F. Mileham, Jiaxin Niu, Elliot Chartash, Corinne Maurice‐Dror, Mark Voskoboynik, Hyun Cheol Chung and D.H. Lee and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Jane Healy

24 papers receiving 768 citations

Hit Papers

First-in-human phase 1 study of the anti-TIGIT antibody v... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
    2021 196 citations Jiaxin Niu, Corinne Maurice‐Dror et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Healy United States 11 335 266 198 175 128 27 772
Hirotake Ichise Japan 15 328 1.0× 448 1.7× 92 0.5× 97 0.6× 113 0.9× 21 781
Marta Koch Belgium 7 292 0.9× 562 2.1× 123 0.6× 37 0.2× 86 0.7× 7 848
Manuela Cominelli Italy 17 203 0.6× 499 1.9× 106 0.5× 149 0.9× 106 0.8× 33 914
Boksik Cha South Korea 16 456 1.4× 591 2.2× 55 0.3× 211 1.2× 426 3.3× 27 1.1k
Lauren M. Goddard United States 8 80 0.2× 396 1.5× 86 0.4× 180 1.0× 163 1.3× 9 868
Heesuk Zang United States 8 159 0.5× 649 2.4× 195 1.0× 65 0.4× 121 0.9× 8 934
Claude Van Campenhout Belgium 16 170 0.5× 360 1.4× 54 0.3× 51 0.3× 68 0.5× 26 711
Lukas Stanczuk Sweden 7 501 1.5× 279 1.0× 34 0.2× 180 1.0× 100 0.8× 8 697
Catherine Clarke United Kingdom 14 313 0.9× 430 1.6× 55 0.3× 94 0.5× 66 0.5× 18 830
Patricia Precht United States 19 148 0.4× 573 2.2× 277 1.4× 57 0.3× 82 0.6× 29 986

Countries citing papers authored by Jane Healy

Since Specialization
Citations

This map shows the geographic impact of Jane Healy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Healy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Healy more than expected).

Fields of papers citing papers by Jane Healy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Healy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Healy. The network helps show where Jane Healy may publish in the future.

Co-authorship network of co-authors of Jane Healy

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Healy. A scholar is included among the top collaborators of Jane Healy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Healy. Jane Healy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Niu, Jiaxin, Ruth Perets, Solange Peters, et al.. (2024). The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. Future Oncology. 20(27). 1983–1991. 8 indexed citations
3.
Rojas, Carlos A., Ferry A.L.M. Eskens, François Ghiringhelli, et al.. (2024). Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.. Journal of Clinical Oncology. 42(16_suppl). 5502–5502. 2 indexed citations
4.
5.
Léary, Alexandra, C. Le Tourneau, Iwona Ługowska, et al.. (2024). 21O Coformulated vibostolimab/pembrolizumab in advanced cervical cancer: KEYVIBE-005. ESMO Open. 9. 103521–103521.
6.
Niu, Jiaxin, Corinne Maurice‐Dror, D.H. Lee, et al.. (2021). First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Annals of Oncology. 33(2). 169–180. 196 indexed citations breakdown →
7.
Garralda, Elena, Ammar Sukari, Nehal J. Lakhani, et al.. (2021). A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.. Journal of Clinical Oncology. 39(15_suppl). 3584–3584. 38 indexed citations
8.
Ahn, M-J., Jiaxin Niu, Dongwook Kim, et al.. (2020). 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC. Annals of Oncology. 31. S887–S887. 26 indexed citations
9.
Niu, Jiaxin, Adnan Nagrial, Mark Voskoboynik, et al.. (2020). 1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC. Annals of Oncology. 31. S891–S892. 19 indexed citations
10.
Gregory, Gareth P., Pier Luigi Zinzani, John Palcza, et al.. (2019). Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study. Clinical Trials. CT106–CT106. 3 indexed citations
11.
Armand, Philippe, Pier Luigi Zinzani, John Palcza, et al.. (2019). Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies. Blood. 134(Supplement_1). 1548–1548. 6 indexed citations
12.
Musa, Hassan, Nathaniel P. Murphy, Jerry Curran, et al.. (2016). Common human ANK2 variant confers in vivo arrhythmia phenotypes. Heart Rhythm. 13(9). 1932–1940. 8 indexed citations
13.
14.
Healy, Jane & Sandeep S. Davé. (2015). The Role of EBV in the Pathogenesis of Diffuse Large B Cell Lymphoma. Current topics in microbiology and immunology. 390(Pt 1). 315–337. 25 indexed citations
15.
Lorenzo, Damaris N., Jane Healy, Janell Hostettler, et al.. (2015). Ankyrin-B metabolic syndrome combines age-dependent adiposity with pancreatic β cell insufficiency. Journal of Clinical Investigation. 125(8). 3087–3102. 15 indexed citations
16.
17.
Healy, Jane, Kent R. Nilsson, Hans E. Hohmeier, et al.. (2010). Cholinergic Augmentation of Insulin Release Requires Ankyrin-B. Science Signaling. 3(113). ra19–ra19. 31 indexed citations
18.
Bennett, Vann & Jane Healy. (2009). Membrane Domains Based on Ankyrin and Spectrin Associated with Cell-Cell Interactions. Cold Spring Harbor Perspectives in Biology. 1(6). a003012–a003012. 150 indexed citations
19.
Bennett, Vann & Jane Healy. (2007). Organizing the fluid membrane bilayer: diseases linked to spectrin and ankyrin. Trends in Molecular Medicine. 14(1). 28–36. 147 indexed citations
20.
Mohler, Peter J., Jane Healy, Hui Xue, et al.. (2007). Ankyrin-B Syndrome: Enhanced Cardiac Function Balanced by Risk of Cardiac Death and Premature Senescence. PLoS ONE. 2(10). e1051–e1051. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hirotake Ichise Breakdown of academic impact, for papers by Marta Koch Breakdown of academic impact, for papers by Manuela Cominelli Breakdown of academic impact, for papers by Boksik Cha Breakdown of academic impact, for papers by Lauren M. Goddard Breakdown of academic impact, for papers by Heesuk Zang Breakdown of academic impact, for papers by Claude Van Campenhout Breakdown of academic impact, for papers by Lukas Stanczuk Breakdown of academic impact, for papers by Catherine Clarke Breakdown of academic impact, for papers by Patricia Precht
Rankless by CCL
2026